All eyes are now on Trius Therapeutics' second ongoing pivotal Phase III trial investigating its antibiotic, tedizolid phosphate, after the company reported positive, if disparate, results from a subgroup analysis of its first Phase III study (TR701-112) of the product in patients with acute bacterial skin and skin structure infections (ABSSSI).
All eyes are now on Trius Therapeutics' second ongoing pivotal Phase III trial investigating its antibiotic, tedizolid phosphate, after the company reported positive, if disparate, results from a subgroup analysis of its first Phase III study (TR701-112) of the product in patients with acute bacterial skin and skin structure infections (ABSSSI).
The new data confirm the drug's efficacy in a subgroup of patients with cellulitis but suggest higher efficacy in European...
The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.
As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
